PriceTargets.com logo

Alimera Sciences - ALIM Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $6.75
  • Forecasted Upside: 221.43%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$2.10 As of 03/31/2023 01:00 AM ET
▲ +0.32 (17.98%)

This chart shows the closing price for ALIM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Alimera Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ALIM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALIM

Analyst Price Target is $6.75
▲ +221.43% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Alimera Sciences in the last 3 months. The average price target is $6.75, with a high forecast of $9.00 and a low forecast of $4.50. The average price target represents a 221.43% upside from the last price of $2.10.

This chart shows the closing price for ALIM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in Alimera Sciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/8/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/6/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/6/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/5/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/3/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/1/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/2/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/1/2023

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/23/2023HC WainwrightReiterated RatingBuy$9.00Low
11/21/2022Alliance Global PartnersDowngradeBuy ➝ Neutral$11.00 ➝ $4.50Low
7/28/2022HC WainwrightBoost TargetBuy$8.00 ➝ $9.00Low
5/10/2022HC WainwrightLower Target$10.00 ➝ $8.00High
2/25/2022Alliance Global PartnersLower Target$14.50 ➝ $11.00High
2/25/2022HC WainwrightLower TargetBuy$12.00 ➝ $10.00High
10/14/2021HC WainwrightReiterated RatingBuy$12.00Low
8/17/2021Alliance Global PartnersLower TargetBuy$16.50 ➝ $14.50High
8/16/2021HC WainwrightLower TargetBuy$16.00 ➝ $12.00High
4/15/2021Alliance Global PartnersBoost TargetBuy$15.00 ➝ $16.50High
4/15/2021HC WainwrightBoost TargetBuy$14.00 ➝ $16.00High
2/26/2021Alliance Global PartnersBoost TargetBuy$12.00 ➝ $15.00Low
7/16/2020HC WainwrightReiterated RatingBuy$14.00Low
7/10/2020HC WainwrightReiterated RatingBuy$14.00Low
4/14/2020HC WainwrightLower TargetBuy$15.00 ➝ $14.00Low
4/7/2020B. RileyLower TargetBuy$24.00 ➝ $15.00Low
2/25/2020HC WainwrightReiterated RatingBuy$15.00High
12/4/2019HC WainwrightReiterated RatingBuy$15.00High
11/18/2019HC WainwrightReiterated RatingBuy$15.00Low
9/30/2019B. RileySet TargetBuy$30.00Low
9/4/2019HC WainwrightSet TargetBuy$30.00Low
6/21/2019HC WainwrightReiterated RatingBuyMedium
5/28/2019Craig HallumInitiated CoverageBuy ➝ Buy$45.00High
5/2/2019HC WainwrightReiterated RatingBuy$45.00Low
3/26/2019HC WainwrightReiterated RatingBuy$41.25Medium
3/7/2019HC WainwrightReiterated RatingBuy$41.25Low
2/20/2019HC WainwrightSet TargetBuy$30.00High
1/8/2019HC WainwrightReiterated RatingBuy$37.50Low
11/27/2018HC WainwrightSet TargetBuy$45.00High
11/7/2018HC WainwrightReiterated RatingBuy$45.00Medium
9/6/2018HC WainwrightSet TargetBuy$45.00Low
9/5/2018CowenReiterated RatingBuy$45.00High
7/31/2018HC WainwrightSet TargetBuy$45.00Low
6/29/2018B. RileyInitiated CoverageBuy$41.25High
6/12/2018HC WainwrightReiterated RatingBuy$45.00Medium
5/8/2018HC WainwrightSet TargetBuy$45.00High
(Data available from 4/1/2018 forward)

News Sentiment Rating

0.39 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/3/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
10/3/2022
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/2/2022
  • 2 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
Mentions as of
12/2/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/1/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/31/2023
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/2/2023
  • 3 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/1/2023

Current Sentiment

  • 3 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Alimera Sciences logo
Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the following geographical segments: U.S. and International. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration and retinal vein occlusion. Its products include ILUVIEN and NADPH Oxidase Inhibitors. The company was founded by Daniel C. Myers and David R. Holland on June 4, 2003 and is headquartered in Alpharetta, GA.
Read More

Today's Range

Now: $2.10
Low: $1.85
High: $2.22

50 Day Range

MA: $2.19
Low: $1.35
High: $2.94

52 Week Range

Now: $2.10
Low: $1.30
High: $7.92

Volume

74,271 shs

Average Volume

40,449 shs

Market Capitalization

$14.70 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.42

Frequently Asked Questions

What sell-side analysts currently cover shares of Alimera Sciences?

The following Wall Street sell-side analysts have issued reports on Alimera Sciences in the last year: Alliance Global Partners, HC Wainwright, and StockNews.com.
View the latest analyst ratings for ALIM.

What is the current price target for Alimera Sciences?

2 Wall Street analysts have set twelve-month price targets for Alimera Sciences in the last year. Their average twelve-month price target is $6.75, suggesting a possible upside of 221.4%. HC Wainwright has the highest price target set, predicting ALIM will reach $9.00 in the next twelve months. Alliance Global Partners has the lowest price target set, forecasting a price of $4.50 for Alimera Sciences in the next year.
View the latest price targets for ALIM.

What is the current consensus analyst rating for Alimera Sciences?

Alimera Sciences currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ALIM will outperform the market and that investors should add to their positions of Alimera Sciences.
View the latest ratings for ALIM.

What other companies compete with Alimera Sciences?

Other companies that are similar to Alimera Sciences include Aeterna Zentaris, CNS Pharmaceuticals, Bio-Path, Lixte Biotechnology and Athersys. Learn More about companies similar to Alimera Sciences.

How do I contact Alimera Sciences' investor relations team?

Alimera Sciences' physical mailing address is 6120 WINDWARD PARKWAY STE 290, ALPHARETTA GA, 30005. The biopharmaceutical company's listed phone number is (678) 990-5740 and its investor relations email address is [email protected] The official website for Alimera Sciences is www.alimerasciences.com. Learn More about contacing Alimera Sciences investor relations.